Spear Bio presented new data examining SPEAR TrueDetect™ epTau 217 performance across paired venous and Tasso capillary blood samples, comparisons with total pTau 217, BD-Tau, and BD-pTau 217, changes in plasma eMTBR-Tau with advancing disease, and associations between eMTBR-Tau, neuropathological severity, and Tau-PET burden in a September 9 webinar.
Public source
Publisher name
Public post
What can distinct Tau biomarkers reveal when evaluated against established measures of Alzheimer’s disease pathology? In our September 9 webinar, Dr. Nicholas Ashton and…
Company
Spear Bio
The first homogeneous immunoassay platform offering unmatched sensitivity with scalable simplicity.
- Industry
- Biotechnology Research
- Location
- Boston, US
- Company size
- 51–200 employees
About Spear Bio
Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio.
See moreLatest activity
Latest activity from Spear Bio
6 signals
Presence & Recognition
Spear Bio and Banner Health will present new data on SPEAR epTau 217 and SPEAR eMTBR-Tau at a 60-minute virtual webinar on Wednesday, September 9.
Partnerships
Spear Bio announced that Microcoat Biotechnologie GmbH is bringing SPEAR technology in-house to expand sponsor access to ultra-sensitive, low-volume biomarker testing within its regulated CRO environment.
Research & Knowledge
Spear Bio reported that SPEAR TrueDetect™ epTau 217 delivered highly consistent measurements across venous blood and Tasso capillary blood samples in paired-sample testing.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Taudia
Taudia held a webinar on AD/PD™ Education on UNLOK on scalable, targeted biomarkers for Alzheimer's disease, covering pTau-217, Aβ42, Aβ40, NfL, and GFAP for a targeted biomarker panel, the SPLASH assay as a new cost-effective, ultrasensitive detection platform, performance data from a 5-plex panel on clinical samples, and preliminary data from eMTBR-tau243 and BD pTau-217 duplex assays for early access.
Research & Knowledge
Diasorin
Diasorin reported that plasma p-tau217 moved primary care physicians from roughly 65% to 93% accuracy in suspected Alzheimer’s off a routine blood draw.
Research & Knowledge
Alamar Biosciences, Inc.
Alamar Biosciences, Inc. published a Biomarker Edge blog by CSO Stephen Williams, MD, PhD, exploring why amyloid alone doesn’t tell the whole Alzheimer’s story and how direct measurement of eMTBR-Tau could help address a critical gap in blood-based Alzheimer’s research.
Research & Knowledge
Neurotrack
Neurotrack's Chief Science Officer Dr. Russell B. breaks down what a positive Alzheimer's blood test can and can't tell a clinician, and why cognitive assessment now does three distinct jobs in the diagnostic pathway.
Research & Knowledge
Harvard Bioscience